Promising outcomes for advanced cancers associated with novel investigational cancer therapeutic
Cambridge, Mass., October 13, 2019 – NED Biosystems, Inc., a clinical-stage biotech company investigating solutions for a broad range of cancers, recently presented its first peer-reviewed data demonstrating that NED-170 may potentially provide advanced-stage cancer patients with a safe, effective, and lower cost alternative to standard chemotherapy. The presentation, a poster on lead therapeutic NED-170, was presented at the American Society of Clinical Oncology, Inc. (ASCO) Breakthrough Summit on October 12, 2019 a premier international cancer meeting taking place in Bangkok, Thailand.
“The results in patients to date with NED-170 offer great hope that a low-toxicity oral treatment may offer a valuable therapeutic alternative for late-stage cancer patients,” said lead author Edward Garmey, MD, scientific advisory board member, NED Biosystems, who also serves as adjunct instructor at Harvard Medical School’s Therapeutics Graduate Program and a member of the Board of Overseers at the Beth Israel Deaconess Medical Center. “It is fitting to me that NED’s first published data were presented at this ASCO Breakthrough Summit, a first-of-its-kind event designed to highlight innovative breakthroughs in cancer care.”
The data presented at the ASCO Breakthrough Summit demonstrated statistically significant tumor growth inhibition in an in-vivo preclinical study comparing NED-170 to standard of care cancer therapy. Clinical case reports of quality of life improvements for patients receiving NED-170 were also presented in the poster. The two NED-170 case studies further demonstrated notable tumor reduction with patient reported improvements in their quality of life. Based on the data presented, NED Biosystems is planning a multinational phase 1/2 clinical trial.
“The NED-170 therapy shows promise and presenting this data as part of the ASCO Breakthrough Summit gave us the opportunity to describe the prospective observational data and patient responses to some of the world’s leading oncologists,” said author Bridget Martell, MA, MD, and scientific advisor to NED Biosystems. “Working on NED-170, a unique and easily-administered combination therapy for late stage patients, is addressing a large unmet medical need among oncology patients – including for those requiring care in developing countries. I look forward to my continued collaboration with the NED team and ultimately bringing this therapy to patients.”
ASCO is the world’s leading oncology organization, representing nearly 45,000 oncology professionals who care for people living with cancer. This year’s inaugural ASCO Breakthrough Summit was the world’s first global summit for oncology innovators.
NED-170 is an oral regimen designed to target five of the essential physiological processes that drive all late stage (stages II-IV) cancer. The regimen consists of 7 components: three FDA-approved drugs and four naturally-occurring compounds combined in particular doses and specific timing, which as a whole have been recognized by the FDA as a unique therapeutic combination and has been granted a composition of matter patent by the U.S. Patent and Trademark Office.
About NED Biosystems™
Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative approaches to cancer treatment. NED Biosystems was founded by Rebecca Lambert, who assembled a team of leading cancer researchers from across the country to develop a drug that simultaneously affects the key processes that drive cancer survival and growth. Ease of oral dosing, favorable storage conditions and cost-effectiveness of the treatment supports the company’s mission to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations but also in the developing world. Visit NEDbiosystems.com.
# # #